Oreofe O Odejide
Overview
Explore the profile of Oreofe O Odejide including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Johnson P, Abramson J, LaCasce A, Armand P, Barnes J, Merryman R, et al.
J Natl Compr Canc Netw
. 2025 Feb;
23(3).
PMID: 39970870
Background: Aggressive non-Hodgkin lymphoma (aNHL) is more common in older adults. Although chemoimmunotherapy can yield durable remissions, it is also associated with significant toxicities. Despite this, longitudinal studies assessing patient-reported...
2.
Odejide O, Cronin A, Gray T, Ablorh T, Ying A, Yang A, et al.
Blood Adv
. 2025 Jan;
PMID: 39841959
Although lymphoma and myeloma confer physical and psychological burden, data are limited regarding anxiety and depression symptoms in affected patients. We conducted a survey between 07/2021 and 09/2022 to characterize...
3.
Odejide O, Cernik C, Uno H, Fisher L, Xu L, Laurent C, et al.
JAMA Netw Open
. 2025 Jan;
8(1):e2454000.
PMID: 39808433
Importance: Adolescent and young adult (AYA) patients with advanced cancer often die in hospital settings. Data characterizing the degree to which this pattern of care is concordant with patient goals...
4.
Cabrera-Perez J, Carey V, Odejide O, Singh S, Kupper T, Pillai S, et al.
J Allergy Clin Immunol
. 2024 Nov;
PMID: 39521279
Background: There have been multiple reports of the anti-IL-4Rα agent, dupilumab, being associated with the onset and/or progression of cutaneous T-cell lymphoma (CTCL). Objective: We sought to evaluate safety signals...
5.
Kuczmarski T, Roemer L, Odejide O
Blood Rev
. 2024 Feb;
65:101182.
PMID: 38402023
Patients with hematologic malignancies experience high rates of depression. These patients are vulnerable to depression throughout the disease trajectory, from diagnosis to survivorship, and at the end of life. In...
6.
Merryman R, Redd R, Freedman A, Ahn I, Brown J, Crombie J, et al.
Ann Hematol
. 2023 Oct;
103(1):185-198.
PMID: 37851072
Antibodies targeting PD-1 or 4-1BB achieve objective responses in follicular lymphoma (FL), but only in a minority of patients. We hypothesized that targeting multiple immune receptors could overcome immune resistance...
7.
Knight H, Brennan C, Hurley S, Tidswell A, Aldridge M, Johnson K, et al.
J Pain Symptom Manage
. 2023 Sep;
67(1):1-9.
PMID: 37777022
Context: Patients with blood cancers have low rates of hospice use. While lack of transfusion access in hospice is posited to substantially contribute to these low rates, little is known...
8.
Gong I, Cheung M, Chan K, Arya S, Faught N, Calzavara A, et al.
J Natl Cancer Inst
. 2023 Aug;
115(10):1194-1203.
PMID: 37531271
Background: Mental disorders have been reported in patients with diffuse large B-cell lymphoma (DLBCL), but studies examining their association with mortality are lacking. Methods: We conducted a population-based study using...
9.
10.
Merrill M, Dahi P, Redd R, McDonough M, Chen Y, DeFilipp Z, et al.
Blood
. 2023 Jun;
142(7):621-628.
PMID: 37319432
Autologous stem cell transplantation (ASCT) is often used as consolidation for several subtypes of peripheral T-cell lymphoma (PTCL) in first remission. However, many patients relapse after ASCT and have a...